Skip to main content


HbAHP-25, a peptide designed in silico, exhibits potent anti-HIV activity in vitro

Article metrics

  • 813 Accesses


Identifying and / or designing molecules that can inhibit HIV infection and be safe to the host cells is highly desired.


HbAHP-25 was designed in silico against CD4 binding domain of gp120 of HIV-1 by molecular docking using Z dock and PROSA softwares. ELISA and SPR were used to determine the binding ability of HbAHP-25 to gp120. Anti-HIV activity of this peptide was checked by two different assays, viz: a) On TZM bl cells, using luciferase assay; b) On CEM-GFP cells and PBMCs using p24 antigen assay. MTT assay, TER/microsphere assay and Immunofluorescence were used to determine the effect of HbAHP-25 on cell viability, epithelial monolayer integrity and permeability.


Five peptides were designed, and one of the peptides, HbAHP-25 , exhibits significant anti-HIV activity against various strains of HIV-1, such as HIV-1 Ada, HIV-1 NL4-3, and HIV-1 IIIB. ELISA and SPR revealed a direct interaction between HbAHP-25 and gp120, thereby inhibiting its interaction with CD4 receptor. The peptide didn’t affect cell viability even at higher concentrations; nor did it affect epithelial monolayer integrity or permeability. HbAHP-25 also did not interfere with any tight junction proteins such as ZO-1 and Clauddin-1, thus maintaining cell integrity as well.


The peptide has potent anti-HIV activity, and can be explored as a potential therapeutic /prophylactic/preventive agent.

Author information

Correspondence to KVR Reddy.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Bashir, T., Kumar, C. & Reddy, K. HbAHP-25, a peptide designed in silico, exhibits potent anti-HIV activity in vitro. BMC Infect Dis 14, E30 (2014) doi:10.1186/1471-2334-14-S3-E30

Download citation


  • Peptide
  • Tight Junction
  • Molecular Docking
  • Tight Junction Protein
  • Affect Cell Viability